Puma Biotechnology, Inc.

$6.99+2.64%(+$0.18)
TickerSpark Score
81/100
Strong
96
Valuation
95
Profitability
20
Growth
92
Health
100
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PBYI research report →

52-Week Range81% of range
Low $3.03
Current $6.99
High $7.90

Companywww.pumabiotechnology.com

Puma Biotechnology, Inc. , a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.

CEO
Alan H. Auerbach
IPO
2012
Employees
172
HQ
Los Angeles, CA, US

Price Chart

+92.56% · this period
$7.80$5.43$3.07May 20Nov 18May 20

Valuation

Market Cap
$355.79M
P/E
14.58
P/S
1.57
P/B
2.77
EV/EBITDA
7.67
Div Yield
0.00%

Profitability

Gross Margin
74.46%
Op Margin
12.98%
Net Margin
10.73%
ROE
20.37%
ROIC
17.12%

Growth & Income

Revenue
$228.37M · -0.91%
Net Income
$31.11M · 2.75%
EPS
$0.62 · 0.00%
Op Income
$37.30M
FCF YoY
7.38%

Performance & Tape

52W High
$7.90
52W Low
$3.03
50D MA
$6.93
200D MA
$5.87
Beta
1.23
Avg Volume
348.44K

Get TickerSpark's AI analysis on PBYI

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Feb 18, 26AUERBACH ALAN Hother159,778
Feb 18, 26AUERBACH ALAN Hother227,474
Feb 18, 26HUNT DOUGLAS Mother49,394
Feb 18, 26HUNT DOUGLAS Mother70,321
Feb 18, 26NOUGUES MAXIMO Fother46,739
Feb 18, 26NOUGUES MAXIMO Fother66,541
Jan 6, 26AUERBACH ALAN Hsell16,938
Jan 7, 26AUERBACH ALAN Hsell18,012
Jan 6, 26HUNT DOUGLAS Msell3,973
Jan 7, 26HUNT DOUGLAS Msell5,014

Our PBYI Coverage

We haven't published any research on PBYI yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate PBYI Report →

Similar Companies